{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:45Z","timestamp":1747181205068,"version":"3.40.5"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:p>The real-world outcomes of lonoctocog alfa (rVIII-SingleChain), a long-acting factor VIII (FVIII) with a favorable safety and efficacy profile in trials, were assessed in patients with hemophilia A in Iberian (Spain and Portugal). This was a retrospective study involving patients switching to rVIII-SingleChain from other FVIIIs in 7 Spanish and Portuguese hospitals. The efficacy and safety of replacement therapies were compared between 12 months before switching and the period from switching to the end of the study. Twenty-nine patients (median age 25 years; severe hemophilia A, 37.9%) were recruited. Before switching, 12 were on prophylaxis and were followed-up for a median of 12 months. After switching, 17 received prophylaxis with rVIII-SingleChain and were followed-up for a median of 41 months. Those with\u2005\u22642 weekly infusions increased from 37.5% before switching to 60.7% after switching to rVIII-SingleChain. The median monthly consumption was 312 IU\/kg with prior FVIIIs and 273 IU\/kg with rVII-SingleChain. Six spontaneous bleeds were reported in each period in the prophylaxis patients. In the entire cohort, 50 bleeds were reported with prior FVIIIs and 33 were reported after switching to rVIII-SingleChain. Patients requiring\u2005\u22641 dose for hemostasis increased from 44.0% with prior FVIIIs to 60.6% with rVIII-SingleChain. Responses were rated good\/excellent in 95.4% of cases. No safety concerns were reported. Patients who switched to rVIII-SingleChain prophylaxis had excellent bleeding control and reduced infusion frequency in regular clinical practice, with the subsequent increase in quality-of-life.<\/jats:p>","DOI":"10.1097\/md.0000000000039255","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:05:07Z","timestamp":1730883907000},"page":"e39255","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Switching hemophilia A patients to rVIII-SingleChain: The Iberian experience"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5408-9264","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Calvo-Villas","sequence":"first","affiliation":[{"name":"Hematology Department, University Hospital Miguel Servet, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramiro","family":"N\u00fa\u00f1ez-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Hemophilia Unit, University Hospital Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Ben\u00edtez-Hidalgo","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Covadonga","family":"Garc\u00eda-D\u00edaz","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernat","family":"Galm\u00e9s","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital Son Espases, Palma de Mallorca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Congenital Coagulopathies Reference Centre, S\u00e3o Jo\u00e3o University Hospital Centre, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Serrano-Torres","sequence":"additional","affiliation":[{"name":"Commonwealth Serum Laboratories (CSL) Behring, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Aznar-Salatti","sequence":"additional","affiliation":[{"name":"Commonwealth Serum Laboratories (CSL) Behring, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"\u00c1lvarez-Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Hematology, La Paz University Hospital, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250505","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using National registries.","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"R2-20250505","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH.","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"R3-20250505","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2516.2009.02032.x","article-title":"Health-related quality of life and productivity impact in haemophilia patients with inhibitors.","volume":"15","author":"Brown","year":"2009","journal-title":"Haemophilia"},{"key":"R4-20250505","first-page":"46","article-title":"Beyond factor replacement therapy: new and experimental agents for hemophilia.","volume":"21","author":"Drygalski","year":"2023","journal-title":"Clin Adv Hematol Oncol"},{"issue":"Suppl 6","key":"R5-20250505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition.","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"R6-20250505","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JBM.S43734","article-title":"Barriers and perceived limitations to early treatment of hemophilia.","volume":"4","author":"Saxena","year":"2013","journal-title":"J Blood Med"},{"key":"R7-20250505","doi-asserted-by":"crossref","first-page":"103678","DOI":"10.1016\/j.critrevonc.2022.103678","article-title":"Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician\u2019s perspective.","volume":"174","author":"Hermans","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R8-20250505","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2014.03.028","article-title":"Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.","volume":"134","author":"Zollner","year":"2014","journal-title":"Thromb Res"},{"key":"R9-20250505","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.12985","article-title":"Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(\u00ae)) in patients with severe haemophilia A.","volume":"22","author":"Klamroth","year":"2016","journal-title":"Haemophilia"},{"key":"R10-20250505","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2016-01-687434","article-title":"Efficacy and safety of rVIII-SingleChain: results of a phase 1\/3 multicenter clinical trial in severe hemophilia A.","volume":"128","author":"Mahlangu","year":"2016","journal-title":"Blood"},{"key":"R11-20250505","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/jth.13647","article-title":"Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.","volume":"15","author":"Stasyshyn","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R12-20250505","doi-asserted-by":"crossref","first-page":"e12665","DOI":"10.1002\/rth2.12665","article-title":"Recombinant single-chain factor VIII in severe hemophilia: long-term safety and efficacy in previously treated patients in the AFFINITY extension study.","volume":"6","author":"Mahlangu","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"R13-20250505","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1007\/s12325-021-01853-0","article-title":"Matching-adjusted indirect comparison of efficacy and consumption of rVIII-SingleChain versus two recombinant FVIII products used for prophylactic treatment of adults\/adolescents with severe haemophilia A.","volume":"38","author":"Bonanad","year":"2021","journal-title":"Adv Ther"},{"key":"R14-20250505","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/ejh.13378","article-title":"Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany.","volume":"104","author":"Olivieri","year":"2020","journal-title":"Eur J Haematol"},{"key":"R15-20250505","first-page":"504","article-title":"Comparing factor use and bleed rates in U.S. hemophilia A patients receiving prophylaxis with 3 different long-acting recombinant factor VIII Products.","volume":"26","author":"Simpson","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"R16-20250505","first-page":"1258","article-title":"A real-world analysis of commonly prescribed FVIII products based on U.S. medical charts: consumption and bleeding outcomes in hemophilia A patients.","volume":"26","author":"Yan","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"Suppl. 2","key":"R17-20250505","first-page":"122","article-title":"Retrospective analysis of rVIII-SingleChain and other commonly used recombinant FVIII products comparing prophylaxis treatment regimens and associated clinical outcomes in haemophilia A patients in Italy [abstract].","volume":"27","author":"Mancuso","year":"2021","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"R18-20250505","first-page":"57","article-title":"Comparison of factor viii utilisation and bleed rates in Italian haemophilia A patients who switched to extended prophylaxis dosing intervals with rVIII-SingleChain [abstract].","volume":"27","author":"Mancuso","year":"2021","journal-title":"Haemophilia"},{"key":"R19-20250505","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1055\/s-0043-1761449","article-title":"A French real-world evidence study evaluating the efficacy, safety, and pharmacokinetic parameters of rVIII-SingleChain in patients with hemophilia A receiving prophylaxis.","volume":"123","author":"Guillet","year":"2023","journal-title":"Thromb Haemost"},{"key":"R20-20250505","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/03007995.2022.2062180","article-title":"Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.","volume":"38","author":"Olivieri","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"R21-20250505","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1055\/s-0043-1761449","article-title":"A french real-world evidence study evaluating the efficacy, safety, and pharmacokinetic parameters of rVIII-singlechain in patients with hemophilia a receiving prophylaxis.","volume":"123","author":"Guillet","year":"2023","journal-title":"Thromb Haemost"},{"article-title":"Systematic review of efficacy and factor consumption of long-acting recombinant factor VIII products for prophylactic treatment of haemophilia A.","year":"2020","author":"Escuriola-Ettingshausen","key":"R22-20250505"},{"article-title":"rVIII-SingleChain in surgical prophylaxis: efficacy and safety of continuous and bolus infusion.","year":"2016","author":"Djambas Khayat","key":"R23-20250505"},{"article-title":"Recombinant factor VIII-SingleChain (lonoctocog alpha) as surgical prophylaxis in patients with haemophilia A.","year":"2021","author":"Benitez Hidalgo","key":"R24-20250505"},{"key":"R26-20250505","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40267-022-00967-x","article-title":"Treatment satisfaction and limitations in haemophilia A, with a focus on factor VIII product storage conditions: patients\u2019 perspectives and challenges.","volume":"39","author":"Zupan","year":"2023","journal-title":"Drugs Ther Perspect"},{"key":"R27-20250505","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/03007995.2022.2116173","article-title":"Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP.","volume":"39","author":"Oldenburg","year":"2023","journal-title":"Curr Med Res Opin"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T20:00:48Z","timestamp":1746475248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":26,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039255","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}